Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 5 May 2025 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for...
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 5 May 2025 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for...